References
- Foran J M, Rohatiner A ZS, Coiffier B, Barbui T, Johnson S A, Hiddemann W, et al. Multicenter phase II study of fludarabine phosphate for patients with newly-diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinaemia, and mantle-cell lymphoma. J Clin Oncol 1999; 17: 546–553
- Zinzani P L, Magagnoli M, Moretti L, De Renzo A, Battista R, Zaccaria A, et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 2000; 18: 773–779
- Decaudin D, Bosq J, Tertian G, Nedellec G, Bennaceur A, Venaut A, et al. Phase II trial of fludarabine monophosphate in patients with mantle cell lymphoma. J Clin Oncol 1998; 16: 579–583
- Cohen B J, Moskowitz C, Straus D, Noy A, Hedrick E, Zelenetz A. Cyclophosphamide/Fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymph 2001; 42: 1015–1022
- Rule S, Burton C, Waleski J, Jack A, Seymour J. A randomised phase II study of fludarabine/cyclophosphamide +/− rituximab in patients with untreated mantle cell lymphoma [abstract]. Ann Oncol 2005; 16(Suppl 5)198a
- Thomas D W, Owen R G, Johnson S AN, Hillmen P, Seymour J F, Wolf M M, et al. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without ritxuimab compared with prior responses to CHOP. Leuk Lymph 2005; 46: 549–552
- Vandenberghe E, Ruiz de Elvira C, Loberiza F R, Conde E, López-Guillermo A, Gisselbrecht C, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793–800
- Geisler C H, Kolstad A, Laurell A, Andersen N S, Pedersen L B, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687–2693
- Ketterer N, Salles G, Moullet I, Dumontet C, Eljaafari-Corbin A, Tremisi P, et al. Factors associated with successful mobilisation of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235–242
- Michallet M, Thiébaut A, Dreger P, Remes K, Milpied N, Santini G, et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 2000; 108: 595–601
- Morgan S J, Seymour J F, Grigg A, Matthews J P, Prince H M, Wolf M M, et al. Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine. Leukaemia 2004; 18: 1034–1038
- Lefrère F, Delmer A, Levy V, Delarue R, Varet B, Hermine O. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 2004; 89: 1275–1276
- Vigouroux S, Gaillard F, Moreau P, Harousseau J, Milpied N. High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica 2005; 90: 1580–1582